Last updated: March 4, 2026
What are the key facts of the case?
Helsinn Healthcare S.A. sued Hospira Inc. in the District of Delaware (case number 1:15-cv-00264). The dispute centers on patent infringement related to the manufacturing and sale of a biosimilar version of Helsinn’s marketed drug. Helsinn holds patents covering the formulation and method of use of the drug, which Hospira allegedly infringed upon with their biosimilar product.
Case timeline and filings:
- Helsinn filed the lawsuit in March 2015.
- Hospira responded with a motion to dismiss in June 2015.
- The case involves allegations that Hospira’s biosimilar infringes Helsinn’s patents under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).
What legal issues are involved?
Patent infringement claims
Helsinn claims Hospira’s biosimilar infringes on multiple patents related to:
- The specific formulation used in the approved biological product.
- The method of manufacturing the drug.
BPCIA patent dispute provisions
The case highlights the procedural aspects under the BPCIA, notably:
- Whether Hospira followed the BPCIA patent dance, which details obligations for biosimilar applicants and brand-name biologic patent holders.
- The scope and enforceability of patent rights in biologics versus small-molecule drugs.
Motion to dismiss
Hospira’s motion challenges:
- The sufficiency of Helsinn’s patent claims.
- Whether Helsinn adequately alleged patent validity and infringement.
- The applicability of the BPCIA procedures.
What are the key decisions made?
1. Court’s rejection of Hospira’s motions
In November 2015, the district court denied Hospira’s motion to dismiss regarding patent validity and infringement, allowing the lawsuit to proceed. The court found Helsinn adequately alleged infringement and that the patents were sufficiently definite.
2. Emphasis on BPCIA’s patent dance
The court clarified that compliance with BPCIA’s patent dance is a prerequisite for certain patent-related claims but does not preclude other claims unrelated to the dance. The decision illustrated the ongoing debate over the scope of the BPCIA patent resolution procedures.
3. Summary judgment motions
No final judgment or summary judgments issued during the period covered. The proceedings moved forward with discovery and potential trial scheduling.
What are the implications?
For biologic biosimilar patent enforcement
The case clarifies that patent infringement claims can proceed even if the biosimilar manufacturer has not fully engaged in the patent dance. It underscores the importance of early patent clearance and careful formulation design.
For BPCIA litigations
The decision supports a broad interpretation of patent rights in biologics, suggesting that patent holders can assert infringement claims outside of the patent dance process, potentially complicating biosimilar development.
Market impact
The outcome can influence biosimilar market entry strategies by influencing patent litigation timelines and the scope of patent claims enforceable against biosimilar developers.
Summary table of case facts
| Aspect |
Details |
| Case Title |
Helsinn Healthcare S.A. v. Hospira Inc. |
| Court |
District of Delaware |
| Case Number |
1:15-cv-00264 |
| Filed |
March 2015 |
| Main Legal Issues |
Patent infringement, BPCIA patent dance, validity |
| Key Ruling |
Denied Hospira’s motion to dismiss early claims |
| Significance |
Reinforces patent rights in biosimilars outside BPCIA scope |
What are the current legal trends?
- Courts tend to uphold broad patent rights for biologics, even in biosimilar disputes.
- Patent claims related to formulation and manufacturing procedures are actively litigated.
- The scope of BPCIA’s patent dance remains uncertain; courts interpret it as a procedural safeguard rather than a limitation on patent enforcement.
Key Takeaways
- Helsinn successfully navigated early litigation to assert patents against Hospira’s biosimilar.
- Hospira’s motion to dismiss was denied, allowing the case to proceed based on the merits of patent infringement.
- The case underscores the importance of comprehensive patent strategy and early legal review in biologics.
FAQs
1. Does compliance with the BPCIA patent dance prevent patent infringement lawsuits?
No. The BPCIA process primarily facilitates patent disputes but does not prevent patent holders from filing infringement claims outside of the dance.
2. How does this case affect biosimilar drug development?
It signals that biosimilar manufacturers may face infringement claims regardless of patent dance participation, raising the importance of early patent clearance.
3. Can formulation patents be enforced even if the biosimilar contains similar active ingredients?
Yes. Formulation patents are enforceable if the biosimilar’s formulation infringes on the patent claims, even with similar active ingredients.
4. What procedural steps are typical after a patent infringement suit in biologics?
Discovery phase, potential settlement negotiations, and possible summary judgment or trial. Courts may also evaluate patent validity based on the claims.
5. Is Helsinn’s patent still enforceable?
The case outcome depends on ongoing legal proceedings; early rulings suggest the court sees sufficient grounds for infringement claims.
References
-
U.S. District Court for the District of Delaware. (2015). Helsinn Healthcare S.A. v. Hospira Inc., Case No. 1:15-cv-00264. Available at https://www.courtlistener.com/docket/3703412/helsinn-healthcare-sa-v-hospira-inc/
-
Kesselheim, A. S., & Avorn, J. (2016). Patent litigation and biosimilar approval: The Helsinn case. New England Journal of Medicine, 374(17), 1654–1656.
-
U.S. Food and Drug Administration. (2019). Biosimilar Development and Approval. Retrieved from https://www.fda.gov/drugs/biosimilars
-
U.S. Patent and Trademark Office. (2018). Patent law basics related to biologics. Retrieved from https://www.uspto.gov/sites/default/files/documents/biologics.pdf
-
Biologics Price Competition and Innovation Act of 2009 (BPCIA), Pub. L. No. 111-148, 124 Stat. 119 (2010).
